DiaSorin

Slight Q4 miss but the 2025 outlook was encouraging

17/03/25 -"DiaSorin’s Q4 results fell somewhat short of market expectations. Sales growth was primarily driven by most segments. For 2025, the company aims for high single-digit growth and enhanced ..."

PDF page sample
Pages
63
Language
English
Published on
17/03/25
Download
You may also be interested by these reports :
08/05/25
Qiagen commenced 2025 positively, with robust performance in Diagnostic Solutions and PCR/Nucleic Acid Amplification, although this was partially ...
08/05/25
Demant’s Q1 results met market expectations. Growth in Hearing Care was counterbalanced by weakness in Hearing Aids. Meanwhile, Diagnostics remained ...
07/05/25
DiaSorin’s Q1 results marginally surpassed market expectations, demonstrating good performance across all segments. Profitability improved and ...
07/05/25
Q2 figures exceeded expectations, surpassing consensus estimates (sales: +2.0%; adjusted EBIT: +4.4%). This was primarily due to pre-buying ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO